Dimensional Fund Advisors’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-422,059
| Closed | -$24.8M | – | 3460 |
|
|
2023
Q4 | $24.8M | Sell |
422,059
-229,663
| -35% | -$12.9M | 0.01% | 1881 |
|
|
2023
Q3 | $28.4M | Buy |
651,722
+179,254
| +38% | +$6.4M | 0.01% | 1722 |
|
|
2023
Q2 | $17.1M | Buy |
472,468
+167,874
| +55% | +$6.92M | 0.01% | 2010 |
|
|
2023
Q1 | $11.3M | Buy |
304,594
+13,735
| +5% | +$618K | ﹤0.01% | 2175 |
|
|
2022
Q4 | $13.2K | Buy |
290,859
+84,355
| +41% | +$5.46M | ﹤0.01% | 2075 |
|
|
2022
Q3 | $14.4M | Buy |
206,504
+28,362
| +16% | +$2.1M | 0.01% | 1997 |
|
|
2022
Q2 | $12M | Sell |
178,142
-11,387
| -6% | -$724K | ﹤0.01% | 2124 |
|
|
2022
Q1 | $15.6M | Buy |
189,529
+104,215
| +122% | +$10.7M | ﹤0.01% | 2102 |
|
|
2021
Q4 | $12.5M | Buy |
85,314
+9,139
| +12% | +$1.42M | ﹤0.01% | 2214 |
|
|
2021
Q3 | $13.5M | Buy |
76,175
+22,556
| +42% | +$3.63M | ﹤0.01% | 2187 |
|
|
2021
Q2 | $8.66M | Sell |
53,619
-1,439
| -3% | -$231K | ﹤0.01% | 2426 |
|
|
2021
Q1 | $9.43M | Buy |
55,058
+12,019
| +28% | +$2.38M | ﹤0.01% | 2352 |
|
|
2020
Q4 | $9.45M | Buy |
43,039
+20,346
| +90% | +$4.4M | ﹤0.01% | 2312 |
|
|
2020
Q3 | $3.77M | Buy |
22,693
+415
| +2% | +$56.8K | ﹤0.01% | 2543 |
|
|
2020
Q2 | $2.54M | Buy |
22,278
+3,246
| +17% | +$315K | ﹤0.01% | 2683 |
|
|
2020
Q1 | $1.46M | Buy |
19,032
+16,984
| +829% | +$1.52M | ﹤0.01% | 2799 |
|
|
2019
Q4 | $264K | Sell |
2,048
-71,017
| -97% | -$6.85M | ﹤0.01% | 3231 |
|
|
2019
Q3 | $5.69M | Sell |
73,065
-950
| -1% | -$89.2K | ﹤0.01% | 2556 |
|
|
2019
Q2 | $7.62M | Sell |
74,015
-362
| -0.5% | -$28.2K | ﹤0.01% | 2489 |
|
|
2019
Q1 | $5.45M | Sell |
74,377
-170,747
| -70% | -$11.6M | ﹤0.01% | 2621 |
|
|
2018
Q4 | $10.4M | Sell |
245,124
-55,933
| -19% | -$2.23M | ﹤0.01% | 2326 |
|
|
2018
Q3 | $14.2M | Sell |
301,057
-13,249
| -4% | -$738K | 0.01% | 2291 |
|
|
2018
Q2 | $15.5M | Sell |
314,306
-20,261
| -6% | -$765K | 0.01% | 2228 |
|
|
2018
Q1 | $10.3M | Hold |
334,567
| – | – | ﹤0.01% | 2371 |
|
|
2017
Q4 | $6.11M | Sell |
334,567
-2,100
| -0.6% | -$32.6K | ﹤0.01% | 2549 |
|
|
2017
Q3 | $3.94M | Buy |
336,667
+137,104
| +69% | +$793K | ﹤0.01% | 2677 |
|
|
2017
Q2 | $728K | Buy |
199,563
+69,377
| +53% | +$266K | ﹤0.01% | 3041 |
|
|
2017
Q1 | $677K | Buy |
+130,186
| New | +$713K | ﹤0.01% | 3047 |
|
Other funds holding MRTX
Dimensional Fund Advisors's MRTX Position: Q1 2024 in Review
Dimensional Fund Advisors sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 422,059 shares — an estimated $24.8M sold.
Dimensional Fund Advisors first reported a position in MRTX in Q1 2017 and held it in 28 quarters. The position peaked at $28.4M in Q3 2023. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.
- Dimensional Fund Advisors reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
- Dimensional Fund Advisors sold 422,059 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $24.8M.
- Dimensional Fund Advisors first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2017 and held it in 28 quarters.
- Dimensional Fund Advisors's Mirati Therapeutics, Inc. Common Stock position peaked at $28.4M in Q3 2023.
- 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.
Based on Dimensional Fund Advisors's 13F filing for Q1 2024, filed 10 May 2024.